Objective-Several lines of evidence implicate CD40 ligand (CD40L, CD154) as a mediator and marker of atherosclerosis.
ble CD40L predict future cardiovascular events in certain patient populations 16, 17 and correlate with several cardiovascular risk factors in pilot studies. 18, 19 Surprisingly, transplantation of either wild-type or CD40L-deficient bone marrow into low-density lipoprotein receptor-deficient mice revealed that CD40L from hematopoietic cells does not contribute to atherogenesis in mice, suggesting that ECs and other resident vascular cells contribute to CD40 signaling in arterial disease. 20 However, knowledge regarding underlying signaling pathways that mediate proatherogenic functions after CD40 engagement in ECs, a key cell type in vascular disease, remains limited. Identification of such pathways has considerable importance, because systemic inhibition of CD40L may have adverse consequences, given this mediator's pivotal function in host defenses. 3, 12, 21 Previous studies focused on CD40 signaling pathways in B lymphocytes. Kinase pathways and tumor necrosis factor (TNF) receptor-associated factors (TRAFs), cytoplasmic adaptor proteins that mediate cytokine signaling of members of the TNF-1, Toll-like-1, and IL-1 receptor superfamilies, may participate in CD40 signaling. 22, 23 The role of TRAFs in ECs remains virtually unexplored. Therefore, this study tested the hypothesis that TRAF-1, -2, -3, -5, and -6 function in CD40L-induced proinflammatory signaling in human and murine primary ECs and whether such signaling functions vary among different CD40L-induced genes in ECs and for the same target gene even among different cell types. We also investigated TRAF expression in murine and human atherosclerotic plaques.
Materials and Methods
Human saphenous vein ECs and human macrophages were isolated, cultured, and stimulated with various cytokines. Expression of TRAF1-6 was assayed by Western blotting of whole-cell lysates and lysates of subcellular protein fractions as described previously. 24 TRAF protein expression was also quantified in lysates from normal and diseased human carotid arteries by Western blotting and in murine aortic sections by immunohistochemistry. Murine ECs isolated from TRAF wild-type and TRAF-deficient mice, as well human umbilical vein ECs, silenced for the respective TRAFs were stimulated with TNF-␣ and CD40L and assayed for IL-6, IL-8, and MCP-1 by enzyme-linked immunosorbent assay (for detailed methods please see http://atvb.ahajournals.org).
Results

CD40L Enhances the Expression of TRAF-1, -2, -3, -5, and -6 Differentially in Human Vascular ECs, SMCs, and Macrophages
All cell types expressed TRAF-1, -2, -3, -5, and -6 constitutively, as determined by Western blot analysis of protein extracts. Ligation of CD40 enhanced the total protein expression of TRAF-1, -2, -3, and -6, but not TRAF-5 in ECs. In SMCs and macrophages, stimulation with CD40L only enhanced TRAF-1 expression (Figure 1) . Notably, other proinflammatory cytokines modulated expression of these TRAFs differently. Stimulation with IL-1␤ or TNF-␣ induced expression of TRAF-1, -3, and -6 in ECs and SMCs, whereas neither stimulus affected the constitutive expression of TRAF-2 or -5 ( Figure 1 ). In contrast, stimulation with interferon-␥ or transforming growth factor-␤ did not change the expression of any TRAF tested in these cell types (Figure 1 ). In macrophages TNF-␣ stimulation only enhanced TRAF-1 expression. Basal TRAF-5 expression was most prominent in macrophages and could be significantly enhanced by stimulation with interferon-␥. The induction of TRAF-1, -2, -3, and -6 expression by CD40L depended on time and concentration, requiring a minimum of 4 hour of stimulation with Ն0.1 g/mL CD40L (supplemental Figure IA and IB, available online at http://atvb.ahajournals.org). To determine tissue expression of TRAFs, protein extracts of nondiseased, atherosclerotic (dichotomized into fibrous or atheromatous plaques as described previously 24 ), or aneurysmal arteries were analyzed by Western blotting. Nondiseased tissue had barely detectable TRAF-1, -2, -3, -5, and -6 expression with the highest amounts of TRAF-6 ( Figure 2B ). In contrast, diseased tissues contained all TRAFs. Compared Figure 1 . CD40L and other proinflammatory cytokines modulate TRAF-1, -2, -3, -5, and -6 differentially in ECs, SMCs, and macrophages. Lysates of ECs, SMCs, and macrophages, incubated with serum-free medium alone (None) or human recombinant IL-1␤ (10 ng/mL), TNF-␣ (50 ng/mL), interferon-␥ (1000 U/mL), CD40L (10 g/mL), or transforming growth factor-␤ (20 ng/mL), were analyzed by Western blotting using the corresponding TRAF antibody. For control purposes, lysates of PMA-activated Jurkat cells were applied (Jurkat).
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with fibrous plaques, atheromatous plaques contained significantly more TRAF-2 and TRAF-3 protein (supplemental Figure III) . However, TRAF-5 abounded in fibrous lesions. Mouse atherosclerotic lesions also contain TRAF-1, -2, -3, -5, and -6 as shown by immunohistochemical study of longitudinal sections of aortas from low-density lipoprotein receptor-deficient mice fed a high-cholesterol diet for 16 weeks ( Figure 3 ). Sections from aortas from mice of similar age fed a regular low-fat diet showed little or no TRAF staining (data not shown). All TRAFs colocalized with both ECs and macrophages as assessed by immunohistochemical study of Murine atheromata (supplemental Figure IV) .
Distinct Roles for TRAF-1, -2, and -5 in CD40L-Induced IL-6 and MCP-1 Expression in Primary Murine ECs
To examine the functional relevance of TRAF-1 for proinflammatory CD40 signaling, we isolated ECs from TRAF-1 wild-type and TRAF-1-deficient mice and analyzed supernatants for an inflammatory response to CD40L. Exposure of CD40L enhanced the constitutive production of IL-6 and MCP-1 protein ( Figure 4A and 4B). Relative levels of IL-6 and MCP-1 release in TRAF-1-deficient ECs exceeded those from wild-type ECs, indicating that TRAF-1 limits CD40 signaling. 25 Stimulation with TNF-␣ also resulted in a relative increase of cytokine expression in TRAF-1-deficient ECs compared with wild-type cells ( Figure 4A and 4B) .
In contrast to TRAF-1, deficiency of either TRAF-2-or TRAF-5 diminished CD40L-inducible and TNF-␣-inducible IL-6 expression ( Figure 4C ). TRAF-2/-5 compound deficiency did not result in a significantly greater reduction in CD40L-inducible or TNF-␣-induced IL-6 expression compared with single gene deficiency ( Figure 4C ). TRAF-2 and/or TRAF-5 deficiency did not modulate CD40L-induced or TNF-␣-induced MCP-1 expression ( Figure 4D ), demonstrating distinct regulation of CD40 signaling for different target genes.
Because previous reports implicated TRAF-1 particularly in the regulation of apoptosis, we investigated whether TRAF-dependent modulation of cytokine expression depends on apoptosis and cell viability. 25 Caspase-3/7 expression did not differ between TRAF-1-deficient cells and wild-type controls. Supernatants from TNF-␣-stimulated TRAF-5-deficient cells had even lower caspase-3/7 expression than in corresponding controls, suggesting lack of dependence of expression of these mediators of apoptosis in these cells (supplemental Figure VA) . Similarly, TRAF-deficient and wild-type Murine cells had comparable cell viability as assessed by lactate dehydrogenase (LDH) release into the supernatant. Only TNF-␣-stimulated TRAF-2/-5 double-deficient cells showed an increased rate of cytotoxicity (supplemental Figure VB) . To ensure that the results obtained in ECs from various tissues can represent those from arterial tissue, we verified some of our findings in ECs isolated from 8 pooled aortas per group (supplemental Figure VIA to VID) . Silencing of TRAFs by siRNA Implicates TRAF-1, -2, -3, -5, and -6 in CD40 Signaling in Human ECs Primary human umbilical vein ECs transfected with TRAF-1-directed siRNA released more IL-6 and MCP-1 but significantly less IL-8 on stimulation with CD40L than those transfected with lamin-directed siRNA, demonstrating that TRAF functions vary for different target genes (supplemental Figure VII) . Transfection with TRAF-2-directed siRNA significantly reduced CD40L-stimulated expression of IL-6 and IL-8 but not MCP-1 compared with anti-lamin-transfected controls, corroborating the concept that this molecule can limit certain proinflammatory aspects of CD40 signaling in ECs. ECs treated with TRAF-5 siRNA showed decreased IL-6 but increased IL-8 expression (supplemental Figure  VII) . Silencing of TRAF-3 in ECs supported an inhibitory role of TRAF-3 in CD40L-induced proinflammatory gene expression, because cells treated with anti-TRAF-3 siRNA showed an increased basal and CD40L-stimulated expression of all 3 proteins. Endothelial cells silenced for TRAF-6 released similar amounts of IL-6 and IL-8 and an increased amount of MCP-1 ( Figure 5 ).
TRAF-1, -2, and -5 Differentially Mediate Proinflammatory Functions of CD40L in Various Cell Types
To test the hypothesis that proinflammatory functions of CD40L not only show target gene selectivity but also differ for the same target gene in various cell types, we isolated peritoneal macrophages from TRAF wild-type and TRAFdeficient animals. Similar to the observations in ECs, TRAF-1-deficient macrophages expressed higher levels of IL-6 and MCP-1 on stimulation with CD40L compared with corresponding wild-type controls. Also, neither TRAF-2 nor TRAF-5 affected CD40L-inducible MCP-1 expression. However, in contrast to ECs, TRAF-5 deficiency did not affect CD40L-induced or TNF-␣-induced IL-6 expression, whereas TRAF-5 deficiency combined with TRAF-2 heterozygosity effectively reduced CD40L-induced and TNF-␣-induced IL-6 expression compared with wild-type controls (supplemental Figure VIII) .
Discussion
This study demonstrates that CD40L and other proinflammatory cytokines differentially modulate TRAF-1, -2, -3, -5, and -6 expression in ECs, SMCs, and macrophages, key cell types in arteries and arterial disease. The results also establish the functional relevance of these TRAFs for proinflammatory signaling events in ECs, and hence in inflammatory vascular diseases such as atherosclerosis.
To date, analysis of TRAF functions after CD40 ligation focused on lymphoid cells and generated inconsistent results, 3, 22, 25 caused in part by diverse methods and cell typespecific and target gene-specific differences in signal transduction mediated by CD40L. Indeed, CD40 signaling may even induce different pathways in the same cell type depending on the stage of differentiation. 23, 26 The present data demonstrate that CD40L uses TRAF-1, -2, -3, -5, and -6 differentially for IL-6, IL-8, and MCP-1 expression in ECs, supporting the concept of target gene-dependent CD40 signaling. Furthermore, TRAF-associated signaling induced by CD40L differs from activation pathways used by other proinflammatory cytokines, as indicated by the distinct modulation of TRAF expression by CD40L compared with IL-1␤, TNF-␣, transforming growth factor-␤, and interferon-␥. In that context, our group recently described that ligation of CD40 on ECs activates Egr-1, a transcription factor not altered by TNF-␣ and IL-1␤ in this cell type. 27 Our observations in macrophages, which contrast in some respects with the findings in ECs, corroborate the notion that CD40 signaling differs not only between different target genes within the same cell type but also for the same target gene in different cell types.
The inducible expression of TRAF-1 by CD40L, IL-1␤, and TNF-␣ in ECs, SMCs, and macrophages observed here agrees with previous reports in B cells and freshly isolated monocytes. 28, 29 The physiological role of TRAF-1 remains controversial. Conflicting reports identify TRAF-1 as either a promoter or an inhibitor of signals triggered by CD40L and TNF-␣ in various cell types. Similarly, others have suggested TRAF-1 as cofactor and inhibitor of TRAF-2-dependent NF-B and JNK activation. 30 -32 Our data demonstrate that TRAF-1 may indeed promote and at the same time inhibit certain proinflammatory functions of CD40L. Thus, TRAF-1 deficiency enhances both CD40L-and TNF-␣-induced IL-6 and MCP-1 expression in ECs, suggesting that TRAF-1 negatively regulates these cytokines in this cell type. Our siRNA studies in human umbilical vein ECs parallel those findings for IL-6 and MCP-1, while suggesting a positive role for TRAF-1 in CD40L-induced IL-8 expression.
In contrast to TRAF-1 and TRAF-5, earlier studies have shown that overexpression of TRAF-2 in cell lines suffices to activate NF-B and JNK. 25, 33, 34 Thus, TRAF-2 likely stimulates signaling by TNF receptor family members, including CD40, in this cell type. However, several reports also described inhibitory signaling functions of TRAF-2 in lymphoid and other cells. 35, 36 The present report identifies TRAF-2 as an activator of CD40L-induced and TNF-␣-induced IL-6 and IL-8 expression in ECs. However, TRAF-2 does not participate in MCP-1 expression initiated by the same cytokines in this cell type.
Similar to TRAF-2 deficiency, TRAF-5-deficient ECs showed significantly reduced CD40L-induced and TNF-␣-induced IL-6 expression compared with wild-type controls. However, ECs treated with TRAF-5 siRNA released significantly more IL-8 protein into the supernatant, suggesting that TRAF-5 mediates and inhibits certain proinflammatory functions of these cytokines. Our data agree with previous reports in B cells, which implicated the participation of TRAF-5 in CD40 and TNF receptor signaling. 34, 37, 38 In contrast to the observations in ECs, TRAF-5 does not mediate CD40L-induced or TNF-␣-induced IL-6 expression in M⌽, an illustration of cell type-selective signaling by these mediators. In B cells, TRAF-2 and TRAF-5 exhibit overlapping functions in CD40 signaling.
Xu et al 39 observed that B cells from TRAF-3-null mice show augmented CD23 and proliferate normally on stimulation with CD40L, suggesting that TRAF-3 does not require CD40 signaling. In contrast, our data demonstrate that ECs treated with siRNA targeting TRAF-3 released significantly more basal and CD40L-induced IL-6, IL-8, and MCP-1 into the supernatant than appropriate control cells, suggesting an inhibitory role for TRAF-3 in CD40 signaling. Our data agree with a previous report by Urbich et al 40 that demonstrated that activation of TRAF-3 by shear stress abrogates CD40L-mediated endothelial activation.
Previous studies on B lymphocytes derived from TRAF-6 -deficient mice suggested that TRAF-6 is instrumental in CD40L-induced proinflammatory cytokine production and B cell maturation. 41 Similarly, Andrade et al and others 42, 43 implicated TRAF-6 as important mediator of CD40 signals in monocytes and macrophages. In contrast to these findings, our siRNA studies suggest that in ECs, TRAF-6, if anything, inhibits CD40L-induced proinflammatory protein expression, highlighting once again cell-type specific differences of TRAF functions. Previous reports implicated TRAF-1 in particular, but also other TRAFs in apoptosis. 44 Our data suggest that TRAFdependent protein expression does not depend on apoptosis and cell viability. We found extensive expression of TRAF-1, -2, -3, -5, and -6 in sections of murine atherosclerotic aortic arches. Co-localization studies confirmed TRAF expression by both ECs and macrophages in situ. Furthermore, lysates of human atherosclerotic and aneurysmal arteries overexpressed TRAFs compared with lysates from apparently normal arteries. These data further support a role for TRAFs in the pathogenesis of atherosclerosis. Interestingly, in contrast to TRAF-1, expression levels of TRAF-2 and -3 were significantly greater in atheromatous lesions compared with fibrous lesions or aneurysmal arteries, whereas fibrous lesions expressed significantly more TRAF-5. Atherosclerotic lesions overexpress CD40L, a mediator that can trigger mechanisms associated with plaque progression and thrombosis. 6, 9, 14, 15, 45 Therefore, high levels of TRAF-2 expression may promote inflammatory signaling by CD40L and other cytokines, potentially linking TRAF-2 not only to atherogenesis but also to plaque complications. Because the same TRAFs may exert opposing functions for different target genes, the net effects of TRAF overexpression on inflammatory activity and atherosclerosis will require future study.
In sum, the present study provides new functional insights into signaling mechanisms initiated by the proatherogenic CD40/CD40L dyad in vascular cells. The results demonstrate that both CD40L and TNF-␣ differentially use TRAF-1, -2, -3, -5, and -6 for proinflammatory signaling depending on the target gene and cell type investigated and directly implicate TRAFs in vascular disease. Manipulation of TRAFs may permit selective modulation of proatherogenic functions of CD40L and other proinflammatory cytokines of the TNF receptor-like and IL-1/Toll-like receptor superfamily. 
